Nanjing Leads Biolabs Co., Ltd.

南京维立志博生物科技股份有限公司

09887.HK

Clinical-stage biotechnology company developing bispecific antibodies and other therapies for oncology, autoimmune, and other severe diseases. Its core product, LBL-024, a PD-L1/4-1BB dual-targeting bispecific antibody, is in registrational trials, with 13 other drug candidates in the pipeline.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Connected or related major customers / suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Adverse change after the track record
• Non-IFRS measures and adjustments
• Material share-based payments
• Chapter 18A biotech